Literature DB >> 18329529

The many faces of scleroderma.

Virginia D Steen1.   

Abstract

Scleroderma autoantibodies are associated with very specific demographic, clinical, organ system, and survival features. The use of scleroderma autoantibodies may be very helpful in determining the prognosis, as well as monitoring and treatment of scleroderma patients. There are many faces of scleroderma that seem to be closely associated with scleroderma autoantibodies. These antibodies should be used in performing clinical trials and in doing genetic and basic research. Hopefully, these scleroderma antibodies will lead to a better understanding of the pathogenesis of scleroderma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329529     DOI: 10.1016/j.rdc.2007.12.001

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  38 in total

Review 1.  N-TproBNP as biomarker in systemic sclerosis.

Authors:  Tommaso Schioppo; Carolina Artusi; Teresa Ciavarella; Francesca Ingegnoli; Antonella Murgo; Silvana Zeni; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 2.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

3.  A 66-Year-Old Woman With Hemoptysis.

Authors:  Falin B Patel; Kara S Couch; Sean McNish; Jonathan D Miller; Robert Siegel; Samantha Easley; Victoria K Shanmugam
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03       Impact factor: 4.794

Review 4.  Systemic sclerosis--challenges for clinical practice.

Authors:  Zsuzsanna H McMahan; Laura K Hummers
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

Review 5.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

6.  Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study.

Authors:  Minoru Satoh; Malgorzata E Krzyszczak; Yi Li; Angela Ceribelli; Steven J Ross; Edward K L Chan; Mark S Segal; Michael R Bubb; Eric S Sobel; Westley H Reeves
Journal:  Arthritis Res Ther       Date:  2011-05-10       Impact factor: 5.156

7.  Expression of TLR7, TLR9, JAK2, and STAT3 genes in peripheral blood mononuclear cells from patients with systemic sclerosis.

Authors:  Miša Vreća; Ana Zeković; Nemanja Damjanov; Marina Andjelković; Milena Ugrin; Sonja Pavlović; Vesna Spasovski
Journal:  J Appl Genet       Date:  2017-11-16       Impact factor: 3.240

8.  Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.

Authors:  D Sánchez-Cano; N Ortego-Centeno; J L Callejas; V Fonollosa Plá; R Ríos-Fernández; C Tolosa-Vilella; G Espinosa-Garriga; D Colunga-Argüelles; M V Egurbide-Arberas; M Rubio-Rivas; M Freire; J J Ríos-Blanco; L Trapiella-Martínez; M Rodríguez-Carballeira; A Marín-Ballvé; X Pla-Salas; C P Simeón-Aznar
Journal:  Rheumatol Int       Date:  2018-01-10       Impact factor: 2.631

9.  Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy.

Authors:  Victoria K Shanmugam; Virginia D Steen
Journal:  Int J Rheumatol       Date:  2010-08-17

Review 10.  Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases.

Authors:  Minoru Satoh; Monica Vázquez-Del Mercado; Edward K L Chan
Journal:  Mod Rheumatol       Date:  2009-03-10       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.